Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
ZJ Roberts, M Better, A Bot, MR Roberts… - Leukemia & …, 2018 - Taylor & Francis
The development of clinically functional chimeric antigen receptor (CAR) T cell therapy is the
culmination of multiple advances over the last three decades. Axicabtagene ciloleucel …
culmination of multiple advances over the last three decades. Axicabtagene ciloleucel …
Advancing CAR T-cell therapy for solid tumors: lessons learned from lymphoma treatment
Chimeric antigen receptor (CAR) immunotherapy is one of the most promising modern
approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah® and …
approaches for the treatment of cancer. To date only two CAR T-cell products, Kymriah® and …
Development and use of the anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel in large B-cell lymphoma: a review
Importance Axicabtagene ciloleucel, an anti-CD19-CD28-CD3ζ chimeric antigen receptor T-
cell therapy, was the first US Food and Drug Administration–approved, genetically …
cell therapy, was the first US Food and Drug Administration–approved, genetically …
[HTML][HTML] Overcoming challenges for engineered autologous T cell therapies
M Better, V Chiruvolu, M Sabatino - Cell and Gene Therapy Insights, 2018 - insights.bio
Axicabtagene ciloleucel is an engineered autologous anti-CD19 chimeric antigen receptor T
cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The …
cell therapy being developed for patients with refractory aggressive B-cell lymphoma. The …